Jane Diggle & Dr Kevin Fernando discuss the management of diabetic kidney disease in relation to the recently published update to NICE guidance on the management of Type 2 Diabetes in adults (NG28)
Insulin in type 2 diabetes – The essentials
Jane Diggle & Nicola Milne take you through the information you need-to-know but sometimes can’t remember on how to maximise the benefits of insulin in your type 2 diabetes patients.
Diabetes Masterclass (1/3): Navigating NICE NG28
Jane Diggle & Dr Kevin Fernando take us through the implementation of the recently published update to NICE guidance on the management of Type 2 Diabetes in adults (NG28) and what it means for primary care.
SGLT2 (5/5) – SGLT2 inhibitors: Latest from NICE
Professor Cliff Bailey and Dr Martin Hadley-Brown provide a 30 minute update on the latest guidance from NICE about SGLT2 inhibitors.
SGLT2 (4/5) – SGLT2 inhibitors: What we need to know from 2021
Professor Cliff Bailey and Dr Martin Hadley-Brown provide a 30 minute update on what you need to know about SGLT2 inhibitors from the 2021 congresses.
SGLT2 inhibitors: The story so far…
Professor Cliff Bailey and Dr Martin Hadley-Brown provide a 30 minute update on what you need to know about SGLT2 inhibitors from the 2021 congresses.
GLP-1 (3/3): Translating theory into practice. An interactive case-based discussion
Su Down and Dr Kevin Fernando translate the theory into practice with case based discussion covering glucose management and initiating GLP-1 RA for CV benefit.
GLP-1 (2/3): Practicalities of starting GLP-1 receptor agonist therapy
Jane Diggle and Nicola Milne discuss GLP-1 Receptor Agonists so you can enhance your knowledge and gain confidence in the practicalities of initiating GLP-1 receptor agonists effectively in daily practice.
GLP-1 (1/3): Understanding the incretin effect and GLP-1 receptor agonist therapy
Jane Diggle and her expert colleagues will discuss GLP-1 Receptor Agonists including ‘Understanding the Incretin effect and GLP-1 Receptor Agonist Therapy’ by Professor Michael Cummings.
SGLT2 (3/5) – SGLT2 inhibitors and the kidney
Professor Cliff Bailey and Dr Pam Brown discuss the Reno-protective effects of SGLT2 inhibitors and the role of SGLT2 inhibitors in the management of diabetic kidney disease.
SGLT2 (2/5) – SGLT2 inhibitors and the heart
Professor Cliff Bailey and Dr Martin Hadley-Brown discuss the effects of SGLT2 inhibitors on cardiovascular function and the role of SGLT2 inhibitors in the management of CV disease.
SGLT2 (1/5) – Understanding SGLT2 inhibition
Professor Cliff Bailey and Professor Vinod Patel assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications.
